Repetitive transcranial magnetic stimulation in combination with paroxetine for major depressive disorder

doi:10.3969/j.issn.1006-7795.2014.02.011

Journal of Capital Medical University ›› 2014, Vol. 35 ›› Issue (2): 194-199.doi: 10.3969/j.issn.1006-7795.2014.02.011

Previous Articles Next Articles

Repetitive transcranial magnetic stimulation in combination with paroxetine for major depressive disorder

Fang Meng¹, Ren Yanping², Liu Hui¹, Zhou Fang¹, Wang Gang^2,3

1. 3rd Ward of Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
2. Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
3. Center of Depression, Beijing Institute for Brain Disorders, Beijing 100088, China

Received:2014-02-18 Online:2014-04-21 Published:2014-04-16
Contact: 王刚 E-mail:gangwangdoc@gmail.com
Supported by:
This study was supported by National Science and Technology Support Program in 11th Five Year Plan of China(2007BAI17B05).

Abstract

Abstract:

Objective To investigate the efficacy of repetitive transcranial magnetic stimulation(rTMS) in combination with paroxetine for major depressive disorder. Methods In a 6-week, randomized, double-blind, sham-controlled trial, 48 patients with major depressive disorder were randomly assigned to receive real or sham rTMS for 2 weeks. During the 6 weeks, paroxetine was used at a fixed dose of 20 mg per day for all participants. Seven sites were set to conduct assessment of efficacy and adverse events in this study. Results The Montgomery-Asberg Depression Rating(MADRS), the 17-item Hamilton Depression Rating Scale(HAMD-17) and Hamilton Anxiety Rating Scale(HAMA) scores significantly decreased from baseline to the endpoint in both groups. No meaningful difference was observed between the two groups in general clinical effect. The mean time-to-onset was earlier by 3 days in Real group, but the difference was not significant. In the Real group, the scores of HAMD anxiety/somatic symptom factor significantly decreased on day10, 14 and 28; the scores of HAMA significantly decreased on day 10. The incidence of adverse events in both groups had no significant difference. Conclusion The combination of rTMS and paroxetine was effective and safe in treatment of MDD. The tendency of fast onset of effect was observed in the comprehensive intervention, which probably is beneficial to the patients with anxiety and somatic symptoms.

Key words: repetitive transcranial magnetic stimulation, major depressive disorder, time-to-onset

CLC Number:

R749.4

Fang Meng, Ren Yanping, Liu Hui, Zhou Fang, Wang Gang. Repetitive transcranial magnetic stimulation in combination with paroxetine for major depressive disorder[J]. Journal of Capital Medical University, 2014, 35(2): 194-199.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.02.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I2/194

References

[1] Stahl S M, Nierenberg A A, Gorman J M. Evidence of early onset of antidepressant effect in randomized controlled trials[J]. J Clin Psychiatry, 2001, 62(suppl 4):17-23.

[2] Entsuah A R, Huang H, Thase M E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo[J]. J Clin Psychiatry, 2001, 62(11):869-877.

[3] Shajahan P M, Glabus M F, Steele J D, et al. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and functional connectivity, but does not impair cognition in major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26(5):945-954.

[4] Fregni F, Santos C M, Myzckowski M L, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2004, 75(8):1171-1174.

[5] Janicak P G, Dowd S M, Martis B, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial[J]. Biol Psychiatry, 2002, 51(8):659-667.

[6] Loo C K, Taylor J L, Gandevia S C, et al. Transcranial magnetic stimulation(TMS) in controlled treatment studies:are some "sham"forms active?[J]. Biol Psychiatry, 2000, 47(4):325-331.

[7] Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial[J]. J Clin Psychiatry, 2005, 66(12):1569-1575.

[8] Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatmen[J]. Lanct, 1997, 349(9065):1594-1597.

[9] Montgomery S A, Bech P, Blier P, et al. Selecting Methodologies for the evaluation of differences in time to response between antidepressants[J]. J Clin Psychiatry, 2002, 63(8):694-699.

[10] 王卓, 王化宁, 陈云春, 等.高频重复经颅磁刺激联合文拉法辛治疗抑郁症的早期疗效[J].临床精神医学杂志, 2012, 22(3):188-190.

[11] Huang M L, Luo B Y, Hu J B, et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder:a double-blind, randomized, sham-controlled trial[J]. Aust NZJ Psychiatry, 2012, 46(3):257-264.

[12] 王文菁, 钟天平.重复经颅磁刺激联合5-羟色胺再摄取抑制剂治疗抑郁症的早期疗效[J].广东医学, 2007, 28(12):1993-1994.

[13] Rumi D O, Gattaz W F, Rigonatti S P, et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind, placebo-controlled study[J]. Biol Psychiatry, 2005, 57(2):162-166.

[14] Mayberg H S, Brannan S K, Mahurin R K. Cingulate function in depression: a potential predictor of treatment response[J]. Neuroreport, 1997, 8(4):1057-1061.

[15] 曹杨, 刘长辉, 吴枫, 等.首发未用药重性抑郁障碍患者生活事件刺激量的研究[J].中国医科大学学报, 2012, 41(3):278-281.

[16] Wassermann E M, Cohen L G, Flitman S S, et al. Seizures in healthy people with repeated "safe" trains of transcranial magnetic stimuli[J]. Lancet, 1996, 347(9004):825-836.

[17] 常凤友.难治性抑郁症的增效治疗[J].中国煤炭工业医学杂志, 2011, 14(11):1730.

[18] 付华斌, 陈峰, 罗克勇, 等.难治性抑郁症的研究进展[J].解放军医药杂志, 2011, 23(3):67-69.

Repetitive transcranial magnetic stimulation in combination with paroxetine for major depressive disorder

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Sun Congcong, Wu Han, Zhou Danna, Jiang Wei, Wang Wen, Yang Chunlin, Ma Xin, Ren Yanping. Brain derived neurotrophic factor as the predictor of efficacy for repetitive transcranial magnetic stimulation in the treatment of refractory depression [J]. Journal of Capital Medical University, 2022, 43(2): 227-232.
[2]	Zhang Yingbin, Mo Linhong, Nie Yiqiu, Liu Aixian. Application of functional near-infrared spectroscopy in the treatment of mild cognitive impairment after stroke with repeated transcranial magnetic stimulation [J]. Journal of Capital Medical University, 2020, 41(6): 965-969.
[3]	Tang Lirong, Zheng Wei, Zhao Xiuqin, Ren Yanping, Xiang Yingqiang, Gao Yue, Xu Qiuyue, Ma Xin. Effects of the structured rehabilitation skills training program in the improvement of depressive symptoms and quality of life in patients with major depressive disorder [J]. Journal of Capital Medical University, 2018, 39(5): 636-640.
[4]	Sun Congcong, Zhou Danna, Ning Fangping, Ma Liang, Yan Liqiong, Ren Yanping, Ma Xin. Augmentation of rTMS in the treatment of refractory schizophrenia [J]. Journal of Capital Medical University, 2018, 39(5): 641-645.
[5]	Li Feng, Bo Qijing, Zhao Yan, Liu Hui, Wang Chuanyue. Quality of life and related factors in patients with major depressive disorder [J]. Journal of Capital Medical University, 2017, 38(2): 186-191.